Skip to main content
Medical information Clinical review pending

Genetic Testing

Oncopro Egfr Arms Pcr Test

The Oncopro EGFR ARMS PCR Test detects mutations in the EGFR gene, guiding personalized cancer treatment decisions, particularly for non-small cell lung cancer. Confirm with the laboratory before booking.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Formalin-fixed paraffin-embedded (FFPE) tissue block containing tumor tissue.
Results
Report available in 4 working days, provided the sample is submitted by Monday 11 am. Confirm with the laboratory before booking.
Preparation
The FFPE tissue block must contain at least 10% tumor tissue for accurate analysis. Confirm with the laboratory before booking.
Test priceKSh 22,230

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Oncopro Egfr Arms Pcr Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Patients diagnosed with non-small cell lung cancer (NSCLC)
  • ✓Individuals being considered for EGFR-targeted therapy
  • ✓Cancer patients where EGFR mutation status impacts treatment decisions
  • ✓Monitoring response to EGFR-targeted therapy (consult physician)
  • ✓Identifying potential resistance mechanisms (consult physician)
02

In plain language

What this test helps you understand

Identifies specific EGFR gene mutations in cancer tissue, guiding the selection of targeted therapies and improving treatment outcomes for certain cancers, particularly non-small cell lung cancer.
The Oncopro EGFR ARMS PCR Test is an advanced diagnostic tool designed to identify mutations in the EGFR (Epidermal Growth Factor Receptor) gene. This gene plays a significant role in the growth and spread of certain cancers, especially non-small cell lung cancer (NSCLC). Understanding these mutations is crucial for doctors to select the most effective, personalized treatment strategies.

This test uses Real Time PCR technology to analyze formalin-fixed paraffin-embedded (FFPE) tissue samples. It specifically looks for mutations that can influence how well targeted therapies work.

Patients diagnosed with non-small cell lung cancer, particularly those being considered for targeted therapy, may benefit from this test. Discuss with your doctor if this test is appropriate for you.

The Oncopro EGFR ARMS PCR Test helps identify specific mutations that can guide treatment choices. This allows doctors to recommend targeted therapies that may lead to better outcomes. The results provide valuable information for monitoring the disease and response to treatment, aiding in informed decision-making between patients and healthcare providers.

Results will indicate the presence or absence of specific EGFR mutations in the provided sample. Discuss the results thoroughly with your oncologist to understand their implications for your treatment plan. Confirm with the laboratory before booking.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationThe FFPE tissue block must contain at least 10% tumor tissue for accurate analysis. Confirm with the laboratory before booking.
SampleFormalin-fixed paraffin-embedded (FFPE) tissue block containing tumor tissue.
MethodologyReal Time PCR (Polymerase Chain Reaction) using ARMS (Amplification Refractory Mutation System) technology.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects specific EGFR mutations. It may not identify all possible mutations or other genetic alterations relevant to cancer. Results are based on the quality and quantity of the submitted tissue sample. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The EGFR (Epidermal Growth Factor Receptor) gene provides instructions for making a protein that helps cells grow, divide, and reproduce. Mutations in this gene can lead to uncontrolled cell growth, contributing to cancer development.
Identifying specific mutations in the EGFR gene helps doctors determine if a patient might benefit from targeted therapies designed to block the activity of the mutated protein, potentially leading to more effective treatment.
A formalin-fixed paraffin-embedded (FFPE) tissue block containing tumor tissue is required. It's important that the block contains at least 10% tumor cells.
Results are typically available within 4 working days, assuming the sample is received by the laboratory by Monday 11 am. Confirm with the laboratory before booking.
The results will indicate whether specific EGFR mutations were detected in the sample. A positive result may suggest eligibility for certain targeted therapies. Discuss the results with your oncologist to understand their implications for your treatment plan.
Insurance coverage varies. Please check with your insurance provider regarding coverage for this specific test.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp